AZD1152 in Diffuse Large B-cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Lymphoma
Interventions
DRUG

AZD1152

Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.

Trial Locations (2)

M20 4BX

Christie NHS Foundation Trust (Christie Hospital), Machester

OX3 7LJ

Oxford Radcliffe NHS Trust (Cancer & Haematology Centre, Churchill Hospital), Oxford

All Listed Sponsors
collaborator

The Christie NHS Foundation Trust

OTHER

collaborator

University of Manchester

OTHER

collaborator

Early Phase Cancer Research Hub, Oxford

UNKNOWN

lead

Oxford University Hospitals NHS Trust

OTHER

NCT01354392 - AZD1152 in Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter